A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab [Rituxan]".

Trial Profile

A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab [Rituxan]".

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Bendamustine (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Cephalon; Salmedix
  • Most Recent Events

    • 01 Jun 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Results published early online in the journal Cancer, according to a media release from Cephalon; they will also appear in a print version of the journal later.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top